Compare DraftKings Inc (DKNG) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Heron Therapeutics Inc — how do they compare? DraftKings Inc trades at $19.9 (market cap $9.51B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: DraftKings Inc is far larger — about 128.4× Heron Therapeutics Inc's market cap, and DraftKings Inc is more actively traded (11,829,779 versus 3,668,095). Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Heron Therapeutics Inc for 35 Days on average.
| DKNG | HRTX | |
|---|---|---|
Market Cap | $9.51B | $74.04M |
Volume | 11,829,779 | 3,668,095 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $1.49 |
52-Week Low | $18.59 | $0.27 |
Typical Hold Time | 55 Days | 35 Days |
Enterprise Value | $10.44B | $180.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.87, near its 52-week low, with a bearish technical outlook despite strong analyst support. The company achieved profitability in 2025 with $6.05B revenue and positive net income of $3.71M, though recent quarters show earnings misses. Operating cash flow improved to $663M in 2025, but high valuation multiples (P/E 246.33) and negative ROE (-22.12%) highlight risks. Recent news focuses on prediction market expansion and NFL season performance.
The stock faces near-term pressure from technical weakness and earnings volatility, but long-term growth drivers in sports betting and predictions remain intact. Wall Street maintains strong bullish sentiment with a $33.13 price target, though investors should weigh high valuation against execution risks and competitive threats in the evolving gaming landscape.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
